These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 531528)

  • 21. Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis.
    Matsuo T; Yamada T; Yamanashi T; Kodama K
    Clin Lab Haematol; 1989; 11(3):213-9. PubMed ID: 2686903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assay of serum abnormalities in uremic and dialysis patients. Evidence for depletion of vital substances in hemodialysis.
    Quadracci LJ; Cambi V; Christopher TG; Harker LA; Striker GE
    Trans Am Soc Artif Intern Organs; 1971; 17():96-101. PubMed ID: 5158140
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasma post-heparin lipolytic activity and triglyceride clearance in uremic and hemodialysis patients and renal allograft recipients.
    Ibels SL; Reardon MF; Nestel PJ
    J Lab Clin Med; 1976 Apr; 87(4):648-58. PubMed ID: 775004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
    Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
    Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alteration of plasma albumin in relation to decreased drug binding in uremia.
    Boobis SW
    Clin Pharmacol Ther; 1977 Aug; 22(2):147-53. PubMed ID: 407044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of hemodialysis and peritoneal dialysis on antithrombin III and platelets.
    Woo KT; Wei SS; Lee EJ; Lau YK; Lim CH
    Nephron; 1985; 40(1):25-8. PubMed ID: 4000334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation.
    Hashimoto K; Yamagishi M; Sasaki T; Nakano M; Kurosawa H
    Ann Thorac Surg; 1994 Sep; 58(3):799-804; discussion 804-5. PubMed ID: 7944706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dialyzable uremic solutes contribute to enhanced oxidation of serum albumin in regular hemodialysis patients.
    Terawaki H; Nakayama K; Matsuyama Y; Nakayama M; Sato T; Hosoya T; Era S; Ito S
    Blood Purif; 2007; 25(3):274-9. PubMed ID: 17460395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antithrombin III activity during hemodialysis].
    Rydzewski A; Soszka J; Myśliwiec M
    Pol Arch Med Wewn; 1983 Feb; 69(2):123-8. PubMed ID: 6889150
    [No Abstract]   [Full Text] [Related]  

  • 30. Antithrombin-III and platelets in haemodialysis patients.
    Brandt P; Jespersen J; Sørensen LH
    Nephron; 1981; 28(1):1-3. PubMed ID: 7266723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The metabolism of human serum albumin in renal failure on conservative and dialysis therapy.
    Bianchi R; Mariani G; Toni MG; Carmassi F
    Am J Clin Nutr; 1978 Sep; 31(9):1615-26. PubMed ID: 685877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Alteration in coagulation and fibrinolysis after burn injury and significance of anticoagulation therapy using heparin and antithrombin III concentrate].
    Ono I
    Hokkaido Igaku Zasshi; 1987 Jan; 62(1):108-21. PubMed ID: 3817736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coagulation activation in extracorporeal hemodialysis.
    Camici M; Evangelisti L; Balestri P; Cioni L; Rindi P; Sagripanti A; Meriggioli M; Giordani R
    Int J Artif Organs; 1997 Mar; 20(3):163-5. PubMed ID: 9151152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of hemodialysis on duodenal and gastric mucosal changes in uremic patients.
    Var C; Gültekin F; Candan F; Türkay C; Sencan M; Içağasioğlu S; Dökmetaş S; Topçu S; Içli F; Var F; Eğilmez R
    Clin Nephrol; 1996 May; 45(5):310-4. PubMed ID: 8738662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of end-stage renal disease and dialysis modalities on blood ammonia level.
    Vaziri ND; Khazaeli M; Nunes ACF; Harley KT; Said H; Alipour O; Lau WL; Pahl MV
    Hemodial Int; 2017 Jul; 21(3):343-347. PubMed ID: 27804262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of desmopressin on protein S and antithrombin III in uremia.
    Akpolat T; Eser M; Albayrak D; Arik N
    Nephron; 1997; 77(3):362. PubMed ID: 9375836
    [No Abstract]   [Full Text] [Related]  

  • 37. First clinical experience with an adjunctive hemoperfusion device designed specifically to remove beta(2)-microglobulin in hemodialysis.
    Ronco C; Brendolan A; Winchester JF; Golds E; Clemmer J; Polaschegg HD; Muller TE; La Greca G ; Levin NW
    Blood Purif; 2001; 19(2):260-3. PubMed ID: 11150821
    [No Abstract]   [Full Text] [Related]  

  • 38. Increased serum midkine levels during hemodialysis using heparin in chronic renal failure.
    Fujisawa K; Matsumoto Y; Muramatsu H; Shinzato T; Hiramatsu K; Horie K; Cai Z; Oka H; Amano I; Muramatsu T; Maeda K
    J Biochem; 1998 May; 123(5):864-9. PubMed ID: 9562618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hemodialysis and long-term erythropoietin treatment on protein C, and on free and total protein S.
    Clyne N; Egberg N; Lins LE
    Thromb Res; 1995 Oct; 80(2):161-8. PubMed ID: 8588193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skin bleeding time for the evaluation of uremic platelet dysfunction and effect of dialysis.
    Soyoral YU; Demir C; Begenik H; Esen R; Kucukoglu ME; Aldemir MN; Demirkiran D; Erkoc R
    Clin Appl Thromb Hemost; 2012; 18(2):185-8. PubMed ID: 22327827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.